Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1412TiP - Mobocertinib (TAK-788) as first-line treatment vs platinum-based chemotherapy (CT) for NSCLC with EGFR exon 20 insertions (exon20ins)

Date

17 Sep 2020

Session

E-Poster Display

Presenters

Pasi Jänne

Citation

Annals of Oncology (2020) 31 (suppl_4): S754-S840. 10.1016/annonc/annonc283

Authors

P.A. Jänne1, Y. Wu2, T. Kato3, B. Besse4, S. Peters5, D. Nguyen6, D. Berg7, J. Lin8, Z. Feng9, T. Mok10

Author affiliations

  • 1 Lowe Center For Thoracic Oncology, Dana Farber Cancer Institute, 2215 - Boston/US
  • 2 Guangdong Provincial People’s Hospital And Guangdong Academy Of Medical Sciences, Guangdong Lung Cancer Institute, Guangzhou/CN
  • 3 Department Of Respiratory Medicine, Kanagawa Cancer Center, 241-8515 - Yokohama/JP
  • 4 Dept Of Cancer Medicine, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 5 Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois - CHUV, 1011 - Lausanne/CH
  • 6 Hematology And Oncology, Pacific Shores Medical Group, Long Beach/US
  • 7 Oncology Clinical Research And Development, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge/US
  • 8 Oncology Statistics, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge/US
  • 9 Clinical Science, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge/US
  • 10 Clinical Oncology, Chinese University of Hong Kong, Shatin/HK
More

Resources

Abstract 1412TiP

Background

∼6% of EGFR-mutated NSCLC tumors have EGFR exon20ins. There are no approved targeted treatments for these patients (pts); approved EGFR TKIs are ineffective, with low response rates and PFS ∼2 mo. Mobocertinib is an oral EGFR TKI under investigation for treatment of NSCLC with EGFR exon20ins. In a phase 1/2 study in previously treated NSCLC with EGFR exon20ins, mobocertinib 160 mg qd demonstrated antitumor activity, with confirmed ORR 43%, mPFS 7.3 mo, and a manageable AE profile similar to other EGFR TKIs. First-line combination CT in this setting yields 1-yr OS 15%–30% and PFS <7 mo. The EXCLAIM-2 trial (NCT04129502) compares efficacy of first-line mobocertinib vs platinum-based CT in NSCLC with EGFR exon20ins.

Trial design

This is a phase 3, open-label trial in adults with locally advanced, recurrent, or metastatic NSCLC with documented EGFR exon20ins with no previous systemic treatment for their disease. Locally advanced disease must be unsuitable for definitive therapy. Pts are randomized 1:1 to receive oral mobocertinib 160 mg qd (arm A) or CT Day 1 every 21 days (arm B; pemetrexed 500 mg/m2 IV with cisplatin 75 mg/m2 or carboplatin AUC 5 mg·min/mL IV for 4 cycles, then pemetrexed maintenance). Pts are stratified by baseline CNS metastases (yes vs no) and race (Asian vs non-Asian) and treated until progressive disease, toxicity, or another discontinuation criterion. Treatment beyond progression or crossover from arm B to arm A following independent review committee (IRC)-assessed PD and meeting crossover eligibility criteria is permitted. Primary endpoint: IRC−assessed PFS per RECIST 1.1 (Table). The study design employs an adaptive event-size reassessment approach for the primary endpoint and a sequential testing procedure for type I error control. The study was initiated in Jan 2020, with ∼170 sites in North America, Europe, Middle East, and Asia-Pacific; ∼318 pts will be randomized. Accrual is ongoing. Table: 1412TiP

Secondary endpoints

IRC-assessed confirmed objective response rate (ORR) Investigator-assessed confirmed ORR Duration of response Time to response Disease control rate Investigator-assessed progression-free survival (PFS) Overall survival Safety/tolerability Patient-reported outcomes (symptoms [core symptoms of lung cancer], functioning, and health-related quality of life) as assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ)-C30 and the lung cancer module, QLQ–LC13

Clinical trial identification

NCT04129502 Release date: October 16, 2019.

Editorial acknowledgement

Professional medical writing assistance was provided by Lauren Gallagher, RPh, PhD, of Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, and funded by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Legal entity responsible for the study

Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Funding

Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Disclosure

P.A. Jänne: Advisory/Consultancy: Araxes Pharmaceuticals; Advisory/Consultancy: ARIAD/Takeda; Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Advisory/Consultancy, Research grant/Funding (self): Boehringer Ingelheim; Advisory/Consultancy: Chugai; Advisory/Consultancy: Ignyta; Advisory/Consultancy, Research grant/Funding (self): Lilly; Advisory/Consultancy, Shareholder/Stockholder/Stock options: Loxo Oncology; Advisory/Consultancy: Merrimack; Advisory/Consultancy: Mirati Therapeutics; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Roche; Advisory/Consultancy: Novartis; Advisory/Consultancy: Voronoi; Advisory/Consultancy, Research grant/Funding (self): Daiichi Sankyo; Advisory/Consultancy: SFJ Pharmaceuticals; Advisory/Consultancy: Biocartis; Research grant/Funding (self): Astellas; Research grant/Funding (self): Puma Biotechnology; Shareholder/Stockholder/Stock options: Gatekeeper; Licensing/Royalties: Dana-Farber Cancer Institute. T. Kato: Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Spouse/Financial dependant: Eli Lilly; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Merck Biopharma; Honoraria (self), Research grant/Funding (self): MSD; Honoraria (self), Research grant/Funding (self): Chugai; Honoraria (self), Research grant/Funding (self): Ono; Honoraria (self), Research grant/Funding (self): Pfizer; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Takeda; Honoraria (self), Research grant/Funding (self): AbbVie; Honoraria (self), Research grant/Funding (self): Novartis; Honoraria (self), Research grant/Funding (self): Taiho; Honoraria (self), Research grant/Funding (self): Bristol-Myers Squibb; Honoraria (self): Daiichi Sankyo; Honoraria (self): Shionogi; Honoraria (self): Nippon Kayaku; Research grant/Funding (self): Regeneron; Research grant/Funding (self): Amgen. B. Besse: Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): Amgen; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): BeiGene; Research grant/Funding (institution): Blueprint Medicines; Research grant/Funding (institution): BMS; Research grant/Funding (institution): Boehringer Ingelheim; Research grant/Funding (institution): Celgene; Research grant/Funding (institution): Cristal Therapeutics; Research grant/Funding (institution): Daiichi Sankyo; Research grant/Funding (institution): Eli Lilly; Research grant/Funding (institution): GSK; Research grant/Funding (institution): Ignyta; Research grant/Funding (institution): Ipsen; Research grant/Funding (institution): Inivata; Research grant/Funding (institution): Janssen; Research grant/Funding (institution): Merck KGaA; Research grant/Funding (institution): MSD; Research grant/Funding (institution): Nektar; Research grant/Funding (institution): Onxeo; Research grant/Funding (institution): OSE Immunotherapeutics; Research grant/Funding (institution): Pfizer; Research grant/Funding (institution): PharmaMar; Research grant/Funding (institution): Roche-Genentech; Research grant/Funding (institution): Sanofi; Research grant/Funding (institution): Servier; Research grant/Funding (institution): Spectrum Pharmaceuticals; Research grant/Funding (institution): Takeda; Research grant/Funding (institution): Tiziana Pharma; Research grant/Funding (institution): Tolero Pharmaceuticals. S. Peters: Advisory/Consultancy: AbbVie, Amgen, AstraZeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp and Dohme, M; Speaker Bureau/Expert testimony: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Illumina, Merck Sharp and Dohme, Novartis, Pfizer, Sanofi, Takeda; Research grant/Funding (institution): Amgen, AstraZeneca, Biodesix, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, F. Hoffmann-La Roche, Illumina, Merck Sharp and Dohme, Merck Serono, Novartis, Pfizer. D. Berg, J. Lin, Z. Feng: Full/Part-time employment: Takeda. T. Mok: Full/Part-time employment: The Chinese University of Hong Kong; Advisory/Consultancy: AstraZeneca, Roche/Genentech, Lilly, Merck Serono, BMS, Pfizer, Boehringer Ingelheim, Novartis, Clovis Oncology, Vertex, SFJ Pharmaceuticals Group, ACEA Biosciences, MSD, geneDecode, Oncogenex, Celgene, Ignyta, Cirina, Hutchison MediPharma; Leadership role: Sanomics Limited, Hutchison MediPharma, AstraZeneca; Shareholder/Stockholder/Stock options: Sanomics Limited, Hutchison MediPharma; Honoraria (self): AstraZeneca, Roche/Genentech, Lilly, Merck Serono, BMS, Pfizer, Boehringer Ingelheim, Novartis, Vertex, SFJ Pharmaceuticals Group, ACEA Biosciences, MSD, Celgene, Ignyta, Hutchison MediPharma, Fishawack Facilitate, Takeda, Janssen; Research grant/Funding (institution): AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, SFJ Pharmaceuticals Group, Roche, MSD, Clovis Oncology, BMS, Xcovery. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings